Chemoprophylaxis refers to the use of chemical agents, such as drugs or medications, to prevent the development or spread of infectious diseases. This proactive approach is often employed in situations where the risk of infection is high, such as during outbreaks or in specific populations with increased vulnerability. Common examples of chemoprophylaxis include the use of antibiotics to prevent bacterial infections, antimalarial drugs for travelers visiting regions with malaria, and antiviral medications for preventing certain viral infections. The choice of the chemoprophylactic agent depends on the specific pathogen and the characteristics of the population at risk. Chemoprophylaxis is widely utilized in public health strategies, such as in the prevention of sexually transmitted infections, tuberculosis, and certain parasitic diseases. The effectiveness of chemoprophylaxis relies on factors like the timing of administration, compliance with the prescribed regimen, and the emergence of drug resistance. While chemoprophylaxis is a valuable tool in disease prevention, its use requires careful consideration of factors such as potential side effects, the development of resistance, and the overall impact on public health. Proper education, monitoring, and adherence to guidelines are crucial for the success of chemoprophylaxis programs.
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : Prophylactic and Molecular Approaches for Mitigating Human Influenza A Viruses: i. Evaluating influenza Vaccine Effectiveness in the Older population ii. Down-regulation of influenza virus genes with novel siRNA-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Development of a Novel Multi-component Vaccine to Address the Burden of Otitis Media in High-Risk Populations
Ayesha Zahid, Griffith University, Australia
Title : Targeting resistance: New 4-substituted pyrazolidine and isoxazolidine as antibiotics with interesting antimicrobial activities
Yousfi Tarek, Nationale Research for Biotechnology Research Center, Algeria
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Immunosuppression in COVID-19 Patients and Emerging Fungal Infections: Vaccines, Diagnosis and Strategies to Treat Comorbidities
K R Aneja, Kurukshetra University, India
Title : Immunogenicity and Cryo-EM structure of native-like HIV-1 Clade-C envelope trimers derived from a pediatric elite-neutralizer
Swarandeep Singh, All India Institute of Medical Sciences, India
Title : Why is the vaccine life-threatening if people get a fever after a COVID-19 vaccination
Yacob Mathai, Marma Health Centre, India
Title : Barriers to polio eradication in South Asia: A systematic review
Awranoos Ahadi, Bolan Medical College, Pakistan